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ABSTRACT
Background Lung cancer is one of the most frequent 
malignancies in humans and is a major cause of death. 
A number of therapies aimed at reinforcing antitumor 
immune response, including antiprogrammed cell 
death protein 1 (anti- PD-1) antibodies, are successfully 
used to treat several neoplasias as non- small cell lung 
cancer (NSCLC). However, host immune mechanisms 
that participate in response to anti- PD-1 therapy are not 
completely understood.
Methods We used a syngeneic immunocompetent 
mouse model of NSCLC to analyze host immune 
response to anti- PD-1 treatment in secondary lymphoid 
organs, peripheral blood and tumors, by flow cytometry, 
immunohistochemistry and quantitative real- time 
PCR (qRT- PCR). In addition, we also studied specific 
characteristics of selected immune subpopulations in ex 
vivo functional assays.
Results We show that anti- PD-1 therapy induces a 
population of circulating T follicular helper cells (cTfh) 
with enhanced B activation capacity, which participates 
in tumor response to treatment. Anti- PD-1 increases 
the number of tertiary lymphoid structures (TLS), which 
correlates with impaired tumor growth. Of note, TLS 
support cTfh- associated local antibody production, which 
participates in host immune response against tumor.
Conclusion These findings unveil a novel mechanism of 
action for anti- PD-1 therapy and provide new targets for 
optimization of current therapies against lung cancer.
BACKGROUND
Lung cancer is the leading cause of death by 
cancer among men and women worldwide. 
Non- small cell lung cancer (NSCLC) accounts 
for up to 85% of all lung cancer cases that 
includes two main entities: adenocarcinoma 
and squamous cell carcinoma. Both are asso-
ciated with a poor prognosis, with a 5- year 
survival rate of <20% of patients.1
Adaptive antitumor immune response 
takes place in secondary lymphoid organs 
(SLOs), where lymphocytes, mainly cytotoxic 
CD8+ T cells, are primed to recognize tumor 
cells and then recruited to tumor microenvi-
ronment to exert their effector function as 
tumor infiltrating lymphocytes (TILs).2 Simi-
larly, antibody production facilitated by CD4+ 
lymphocyte help also occurs in SLOs, within 
specialized structures called germinal centers 
(GC).2 Follicular helper T cells (Tfh) consti-
tute a specialized subset of CD4+ T lympho-
cytes that localizes in close interaction with B 
cells in GCs, and collaborates in the gener-
ation of high- affinity antibody responses. 
Mature Tfh cells participate in somatic hyper-
mutation processes and clonal selection of 
GC B cells.3 One hallmark of the adaptive 
immune system is the generation of immuno-
logical memory. Several studies support the 
notion that GC responses generate memory 
Tfh in addition to memory B cells. Recently, a 
new subset of CD4+ T lymphocytes with Tfh- 
like immunophenotype (CD4+CXCR5+pro-
grammed cell death protein 1 (PD-1)+CCR7 
low) were identified in peripheral blood 
of human and mice.3 These circulating Tfh 
(cTfh) are associated with a memory- like 
function, since they can reactivate after 
dendritic cell re- encounter, home to GCs and 
produce more cytokines than their GC coun-
terparts.4 Likewise, some authors suggest 
that cTfh could provide robust B cell help 
during secondary antigen exposure to induce 
strong antibody responses,5 and discriminate 
among functional subpopulations of cTfh 
with different B activation capacity based on 
their expression of markers such as CXCR3, 
ICOS, PD-1 and CCR7.4–6 However, neither 
the specific precursor of cTfh cells nor the 
potential role of cTfh in antitumor immune 
response have been defined yet.
Adaptive antitumor response occurs at 
SLOs and in certain organized structures in 
tumor sites, called tertiary lymphoid struc-
tures (TLS).7 TLS are ectopic organized 
lymphoid aggregates comprised of distinct 
T- cell and B- cell zones, which reflect lymphoid 
neogenesis occurring in peripheral tissues. 
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TLS presence is associated with favorable prognosis in 
most solid malignancies including NSCLC,8 as they help 
local presentation of tumor antigens to T cells, together 
with activation and differentiation of T and B cells.9 
Local production of proinflammatory cytokines recruits 
lymphoid tissue inducer (LTi) cells to the site of inflam-
mation. These LTis interact with stromal cells present 
in tumor microenvironment, which resemble lymphoid 
tissue organizers in SLOs. This initial phase of priming 
leads to secretion of chemokines as CXCL12, CXCL13, 
CCL19 and CCL21. These factors promote recruitment 
of lymphoid cells to the site of inflammation and regulate 
their organization in T- cell and B- cell zones.10 11
Tumors have developed different strategies to escape 
antitumor immune response.12 Among these mecha-
nisms, the role of PD-1- ligand 1 (PD- L1) axis was studied 
in depth because of its inhibitory function on T lympho-
cytes.13 14 However, PD-1 ligation triggers inhibitory 
signals in T lymphocytes, and participates in positioning 
and differentiation of Tfh cells within SLOs. Hence, PD-1 
interacts with PD- L1 expressed by bystander B cells in 
GCs, restraining PI3K signaling necessary for Tfh motility 
downstream CXCR5- CXCL13 interaction. Additionally, 
PD-1 limits CXCR3 expression to confine Tfh cell inside 
the GC.15 Nevertheless, the precise mechanisms impli-
cated in regulation of Tfh positioning and differentiation 
have not been defined at the time of writing.
As a result of PD-1 role in restraining host antitumor 
immune response, multiple clinical agents have been 
developed that target this molecule to treat patients with 
cancer. Hence, two monoclonal antibodies targeting 
PD-1, that is, nivolumab and pembrolizumab, have shown 
outstanding results in clinical trials,16–18 gaining Food and 
Drug Administration (FDA) approval as first- line therapy 
in several cancers (https://www. fda. gov/).
In the present study, we addressed the role of cTfh in 
antibody- mediated antitumor immune response following 
anti- PD-1 therapy, using a syngeneic immunocompetent 
mouse model of NSCLC. Our results demonstrate that 
anti- PD-1 induces a cTfh subpopulation with enhanced 
B activation capacity, associated with tumor response 
to treatment. We also show that anti- PD-1 increases the 
number of TLS, which support cTfh- associated antibody 
production and correlate with reduced tumor growth. 
These findings reveal a novel role of PD-1 in host immune 
response against lung cancer, and uncover previously 
unidentified mechanisms of action of anti- PD-1 therapy.
METHODS
Cell lines and lentiviral production
Mouse lung squamous cell carcinoma KLN205 cell line 
was purchased from Sigma- Aldrich (USA) and cultured 
in Eagle's Minimum Essential Medium (EMEM) supple-
mented with 10% heat- inactivated fetal bovine serum 
(Fisher Scientific, USA), 1X penicillin- streptomycin 
solution (Biowest, France), 2 mM L- glutamine (Lonza, 
Switzerland) and 1X non- essential amino acid solution 
(Lonza, Switzerland), at 37°C and 5% CO2.
To generate KLN205- Luc cell line, KLN205 cells were 
transduced with  pHRSIN- CS- Luc- WdlNotI. str lentiviral 
vector19 encoding luciferase gene, to allow tumor moni-
toring in mice. Lentiviral particles were produced in 
HEK- 293T cells (ATCC, USA) by calcium phosphate tran-
sient transfection method. After 48 hours supernatants 
were collected and concentrated by ultracentrifugation 
at 26 000 rpm for 2 hours at 4°C.
Mice and tumor model
All mouse studies were performed using DBA/2JRj male 
mice aged 12 weeks (Janvier Labs, France). KLN205 
tumor cells were implanted subcutaneously, and tumor 
growth was monitored by bioluminescence with an in vivo 
image system (Vivo Vision IVIS 200) (PerkinElmer, USA), 
after intraperitoneal injection of 1.25 mg of D- luciferin 
per mouse. Bioluminiscence was quantified with Living 
Image software (PerkinElmer), and animals were homo-
geneously sorted into treatment groups. For anti- PD-1 
(clone RMP1-14, Bio X Cell, USA) and isotype- matched 
(clone 2A3, Bio X Cell) antibody treatment, mice were 
injected with 200 µg of antibody intraperitoneally each 
3–4 days. Tumors were harvested after 14 days of treat-
ment initiation unless otherwise indicated.
Flow cytometry
Samples were blocked with mouse FcR Blocking Reagent 
(MiltenyiBiotec, USA), and then stained with the indi-
cated antibodies. The antibodies included APC/Cy7 
anti- interferon (IFN)γ, APC/Cy7 anti- CD38, BV421 
anti- CCR7, BV510 anti- CXCR3, PerCP/Cy5.5 anti- 
CXCR5, biotinylated anti- CXCR5 from Biolegend (USA); 
AF488 anti- CD4, eFluor506 anti- IL17A, PE anti- IL21, 
PE- Cy7 anti- CD44, PE- Cy7 anti- FoxP3 from eBiosciences 
(USA); FITC anti- CD69, PE anti- CD25, PerCP anti- CD3e, 
PE- Cy7 anti- IL4 from BD Biosciences (USA); biotinylated 
anti- PD-1 from R&D systems (USA) and streptavidin- APC 
from Jackson Immunoresearch (USA). When necessary, 
red blood cell lysis was performed using BD Pharm Lyse 
lysing buffer (BD Biosciences). For intracellular staining, 
CytoFix/Perm kit (BD Biosciences) or FoxP3/Transcrip-
tion Factor Staining Buffer Set (eBiosciences) were used 
according to the manufacturer’s instructions. Cytometric 
data were collected using an FACS Canto II (BD Biosci-
ences) and analyzed using FlowJo software (BD Biosci-
ences). Gating strategy is shown in online supplemental 
figure 4.
Cell cultures and isolation
For in vitro assays, CD4+ T cells were isolated from 
either peripheral blood or spleens of mice by negative 
selection using EasySep Mouse CD4+ T cell Isolation Kit 
(StemCell Technologies, Canada). Then, CXCR5+PD-1+ 
Tfh cells were further purified from isolated CD4+ T 
cells using Streptavidin MicroBeads in an autoMACs 
Separator (MiltenyiBiotec). In parallel, naïve T cells were 
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purified by negative selection from isolated CD4+ T cells 
by adding biotinylated anti- CD25 (BD Biosciences, USA) 
to an EasySep Mouse Memory T cell Depletion Cocktail 
(StemCell Technologies, Canada).For T cell activation 
assay, 4×104 naïve T cells, cTfh and spleen Tfh from anti- 
PD-1- treated and isotype- treated mice were stimulated 
with Phorbol 12- myristate 13- acetate (PMA)(20 ng/
mL) (Merck, Germany) plus ionomycin (1 µM) (Merck, 
Germany) for 5 hours. Brefeldin A (Merck, Germany) 
was added for the last 2 hours to allow intracellular cyto-
kine accumulation prior to flow cytometry staining.
Antibody detection by ELISA and immunofluorescence
Serum levels of IgM were determined in anti- PD-1- treated 
and isotype- treated mice using the Mouse IgM ELISA 
Quantitation set (Bethyl, USA) following the manufac-
turer’s indications. Autoantibodies were detected by incu-
bating HEp-2 ANA Slides and Rat Liver/Kidney/Stomach 
Slides (Inova Diagnostics, USA) with sera from mice with 
different treatments, and AF488 antimouse IgG (Life 
Technologies, USA) was used as secondary antibody for 
detection.
Immunohistochemical analysis
Tumors and spleens from anti- PD-1- treated and isotype- 
treated mice were fixed in 4% paraformaldehyde and 
embedded in paraffin; 3 µm sections were stained with 
H&E (Casa Álvarez, Spain). Additionally, samples were 
stained with m- IgG kappa (IgGk) BP- HRP (Santa Cruz 
Biotechnology, USA), anti- PD-1 (R&D systems), anti- 
CD4, anti- CD20 (Abcam, USA) and anti- Ki67 (Invitrogen, 
USA) antibodies. For immunofluorescence staining, 
tissue sections were incubated with primary antibody 
overnight at 4°C and then with secondary Alexa Fluor 647 
anti- IgG (H+L), Alexa Fluor 555 anti- IgG (H+L) antibody 
or Alexa Fluor 647 Streptavidin (Invitrogen) for 30 min at 
room temperature. Finally, sections were counterstained 
with 4′,6- Diamidino-2- phenylindole (DAPI) (Invitrogen) 
and evaluated by confocal laser scanning microscopy 
(acquired with a TCS SP5 microscope and processed with 
LAS- AF software; Leica, Germany).
TLS were defined as areas of dense and localized 
lymphocyte infiltration inside tumors or in their inva-
sive margins. PD-1 and Ki67 expression was expressed 
as the percentage of positive cells in the selected area 
(TLS in tumors or GC in spleens) using ImageJ soft-
ware. We considered three organization degrees within 
TLS as follows: grade I for localized but non- structured 
lymphoid aggregates with diffuse borders, grade II for 
discrete follicle- like structures without apparent GCs and 
grade III for follicle- like structures which contain distinct 
GCs. IgGk expression was estimated as the percentage of 
TLS positive for IgGk staining. Tumor size (S) was calcu-
lated from formalin- fixed paraffin- embedded (FFPE) 
sections using the formula S=(π×L×W), where L is the 
largest tumor diameter and W the perpendicular tumor 
diameter.
Chemokine expression analysis
Total RNA was isolated from tumor FFPE slices using a 
Maxwell RSC RNA FFPE Kit in a Maxwell RSC device 
(Promega, USA), following the manufacturer’s instruc-
tions. RNA was reverse transcribed to cDNA using the 
GoScript Reverse Transcription System (Promega). 
Quantitative real- time PCR (qRT- PCR) was performed 
with SYBR Green (Promega) in a CFX384 (BioRad, 
USA) and a QuantStudio 5 (Applied Biosystems, USA) 
detection systems. Primers used for qRT- PCR are listed in 
online supplemental table 1. β-Actin mRNA levels were 
used for normalization.
Statistics
Statistical analysis was carried out with Prism 5 (GraphPad 
Software). Data are presented as mean±SD unless other-
wise specified. For comparison between populations, 
unpaired two- tailed Student’s t- test or analysis of variance 
analysis was performed, as appropriate. For correlation 
analyses, Spearman’s coefficient r or Pearson’s r were 
calculated. P values <0.05 were considered to be statisti-
cally significant.
RESULTS
Anti-PD-1 treatment induces a population of circulating Tfh 
with enhanced helper capacity in peripheral blood
To assess the effect of anti- PD-1 therapy on immune 
response against tumors in our model, we first analyzed 
the profile of immune cells from peripheral blood, SLOs 
and TILs obtained from tumor- bearing mice after anti- 
PD-1 or isotype treatment. To this end, we inoculated 
DBA/2JRj mice subcutaneously with syngeneic NSCLC 
KLN205 cells. Mice treated with control antibody showed 
progressive tumor growth, while treatment with anti- 
PD-1 clearly impaired tumor development (figure 1A). 
We analyzed the distribution of immune cell subpopula-
tions in both groups, and detected a significant increase 
in cTfh (CD4+PD-1+CXCR5+ cells) in peripheral blood 
of mice treated with anti- PD-1 antibodies. This increase 
was not observed in SLOs, which had comparable Tfh 
levels in both anti- PD-1- treated and isotype- treated mice 
(figure 1B,C). We performed CD25 and FoxP3 staining 
of blood and spleen Tfh cells, finding a significant reduc-
tion in follicular regulatory T cells (Tfr)/Tfh propor-
tion between anti- PD1- treated and isotype- treated mice 
in peripheral blood but not in spleen, thereby ruling 
out a parallel increase in Tfr induced by PD-1 treatment 
(figure 1F).
To further characterize this population, we analyzed 
the expression of CD38, CXCR3 and CCR7 surface mole-
cules, critically involved in Tfh function.6 We found that 
CXCR3 was reduced in cTfh from anti- PD-1- treated mice, 
while CD38 was significantly increased and CCR7 expres-
sion was comparable in cTfh from both groups. Of note, 
the immunophenotype of spleen Tfh cells was similar 
between treatments (figure 1D,E). These data indicate 
that anti- PD-1 therapy induces an increase of activated 
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Figure 1 Antiprogrammed cell death protein 1 (anti- PD-1) treatment induces circulating T follicular helper cells (cTfh) in non- 
small cell lung cancer (NSCLC)- bearing mice. (A) Anti- PD-1 therapy reduces tumor development in KLN205 murine model of 
NSCLC. Graph represents tumor development in isotype- treated or anti- PD-1- treated mice (n=9) estimated as percentage 
of tumor size at the onset of therapy, measured by bioluminescence. (B) Quantification of follicular helper T cells (Tfh) as 
percentage of CD4+ T cells in peripheral blood (isotype n=29 and anti- PD-1 n=26), spleen (isotype n=18 and anti- PD-1 n=15) 
and draining lymph nodes (isotype n=8 and anti- PD-1 n=9) from isotype- treated and anti- PD-1- treated mice. (C) Plots show 
representative CXCR5 and PD1 surface staining of Tfh lymphocytes from peripheral blood and spleen of anti- PD-1- treated and 
isotype- treated mice. Percentages of each subpopulation are indicated. (D) Percentage of CD38, CXCR3 and CCR7 expression 
in Tfh from peripheral blood and spleens of anti- PD-1- treated or isotype- treated mice; n=9 for peripheral blood and n=12 for 
spleen of isotype- treated mice, and n=15 for both peripheral blood and spleen of anti- PD-1- treated mice. (E) Representative 
histograms of surface markers showed in (D). (F) Follicular regulatory T cells (Tfr)/Tfh lymphocyte proportion in spleen (left) and 
peripheral blood (right) of anti- PD-1- treated and isotype- treated mice (n=8 and n=4, respectively for peripheral blood and n=3 
for spleen). Tfr and Tfh percentages (referred to CD4+ lymphocyte population, mean±SD) are the following: spleen, Tfr- isotype 
0.49%±0.36%; Tfr- anti- PD-1 1.13%±0.53%; Tfh- isotype 2.5%±0.04%; Tfh- anti- PD-1 4.82%±2.19%; peripheral blood, Tfr- 
isotype 0.385%±0.22%; Tfr- anti- PD-1 3.82%±1.19%; Tfh- isotype 1.6%±1.2%; Tfh- anti- PD-1 63.55%±18.5%. Tfr population 
was quantified as CD25+FoxP3+ cells within CD4+CXCR5+PD-1+ cells. ns, not significant. *P<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.
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cTfh in peripheral blood of treated mice, which display 
an immunophenotype compatible with a helper subpop-
ulation. To gain insight into functional attributes of these 
cells, we measured cytokine production by cTfh and naïve 
CD4+ T cells from peripheral blood of anti- PD-1- treated 
and isotype- treated mice. Isolated cTfh were cultured in 
vitro with PMA/ionomycin (P/Io) for 5 hours, and intra-
cellular staining of interleukin (IL)-21, IL-4, IL-17 and 
IFNγ was performed. A selective induction of IL-21 and 
IL-4 was observed in cTfh from anti- PD-1- treated mice as 
compared with the isotype group (figure 2A). Conversely, 
both anti- PD1- treated and isotype- treated spleen Tfh 
showed a modest increase in IL-21 production on P/Io 
treatment, with no variation in IL-4 level in any condi-
tion (figure 2A,B). Effective cell activation by P/Io in 
all cases was confirmed through CD69 surface staining 
(figure 2C). We found no differences in IL-21 or IL-4 
expression in P/Io- stimulated CD4+ T- naïve lymphocytes 
from any condition (figure 2D,E). Altogether, these data 
suggest that anti- PD-1 treatment specifically induces a 
circulating Tfh population with increased B cell activa-
tion capacity.
Contribution of anti-PD-1 to antitumor antibody response
To evaluate whether there was a parallel in vivo B cell 
activation response in anti- PD-1- treated mice, we first 
analyzed Ig levels in the serum of mice treated with either 
anti- PD-1 or isotype control antibodies. Tumor devel-
opment induced a significant increment of serum IgM 
concentration, which was further increased by anti- PD-1 
therapy (figure 3A).
To assess the effective production of antibodies directed 
against tumor cells, we carried out flow cytometry exper-
iments with KLN205 cells incubated with sera from 
control and tumor- bearing mice. Unlike control animals, 
positive surface staining could be detected with sera from 
tumor- bearing mice (figure 3B). Parallel experiments 
with non- related B16 murine melanoma cells showed 
no staining in either condition (figure 3B). In addition, 
several autoimmune adverse effects were described in 
patients undergoing therapy with immune checkpoint 
inhibitors20; we, therefore, analyzed whether the increase 
of Ig level in anti- PD-1- treated mice was associated with 
the development of an autoimmune condition. Immu-
nofluorescence assays revealed the appearance of auto-
antibodies in parallel to tumor development, whose 
titer slightly decreased with anti- PD-1 treatment (online 
supplemental figure 1), suggesting a paraneoplastic auto-
immune syndrome, unrelated with anti- PD-1 therapy.
Altogether, these data show that tumor growth is asso-
ciated with the development of an antitumor humoral 
response, which is further enhanced by anti- PD-1 
treatment.
Anti-PD-1 promotes germinal center reaction in spleen
To assess the presence of GCs in SLOs, we analyzed expres-
sion and distribution of PD-1 and Ki67 markers by immu-
nohistochemistry in spleens of tumor- free (control), 
anti- PD-1- treated and isotype- treated mice. Tfh present in 
GCs express high levels of surface PD-1, and secrete ILs 
that promote proliferation, survival and differentiation of 
B lymphocytes. For this reason, we analyzed expression 
and distribution of PD-1 and Ki67 markers by immunohis-
tochemistry in spleens of tumor- free (control), anti- PD-1- 
treated and isotype- treated mice. We confirmed by CD4 
staining that PD-1 expression in GCs corresponded to 
Tfh (online supplemental figures 2A and 4A). Similarly, 
we verified through CD20 staining that GC Ki67+ cells 
represented proliferating B lymphocytes (online supple-
mental figure 2A). We could detect a limited number of 
cells positive for either PD-1 or Ki67 staining in control 
mice (online supplemental figure 2B). However, tumor 
development was accompanied by the presence of both 
PD-1 and Ki67+ splenic GCs, which was further increased 
by anti- PD-1 treatment; likewise, the proportion of PD-1+ 
and Ki67+ cells inside GCs was significantly higher in 
anti- PD-1- treated mice (figure 4B,C). Notably, we could 
establish a significant correlation between PD-1 and Ki67 
expression in GCs, probably reflecting Tfh- dependent B 
cell activation in these structures (figure 4D). Neverthe-
less, we did not find any significant relationship between 
expression of either PD-1 or Ki67 in splenic GCs and 
tumor response to anti- PD-1 treatment (figure 4E). These 
data support that anti- PD-1 therapy promotes in vivo B 
cell activation in spleen, which is not associated with 
tumor sensitivity to treatment.
Anti-PD-1 therapy increases tumor TLS number and promotes 
in situ antibody generation
Since we did not find any correlation between Tfh- 
dependent B cell activation in spleen and tumor response 
to therapy, we evaluated the potential contribution of 
tumor ectopic lymphoid structures to antitumor immune 
response. We first quantified TLS in tumor samples from 
isotype- treated and anti- PD-1- treated mice, and observed 
a significant increase in TLS number in tumors from anti- 
PD-1- treated mice, which displayed higher degree of orga-
nization than isotype- treated control group (figure 5A 
and online supplemental figure 3A), and inversely 
correlated with tumor size (figure 5A). A wide range of 
inflammatory and chemoattractant factors are involved in 
migration of immune cells to tumor microenvironment 
and regulation of different stages of TLS development.21 
To study the implication of these factors in anti- PD-1- 
induced TLS formation, we analyzed mRNA expression 
level of lymphotoxin (LT)-α, LT-β, tumor necrosis factor 
(TNF-α, CCL19, CCL21, CXCL12, CXCL13, CXCL9 
and CXCL10 in tumor samples from anti- PD-1- treated 
and isotype- treated mice. Strikingly, CCL21 was the only 
chemokine with a significant increase in anti- PD-1- treated 
mice, while reduced expression of LT-α and LT-β, TNF-α, 
CXCL12 and CXCL13 was detected in these mice. CCL19, 
CXCL9 and CXCL10 mRNA expression remained unal-
tered (figure 5B and online supplemental figure 3B). In 
addition, CCL21 increase secondary to anti- PD-1 treat-
ment was directly related to both TLS presence and 
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Figure 2 B cell activation capacity of follicular helper T cells (Tfh) from isotype- treated and antiprogrammed cell death protein 
1 (anti- PD-1)- treated mice. (A) Quantification of interferon (IFN)γ, interleukin (IL)-4, IL-17 and IL-21 production in circulating T 
follicular helper cells (cTfh) and Tfh from spleen of anti- PD-1- treated and isotype- treated mice. For stimulation experiments, Tfh 
were isolated and pooled from isotype- treated and anti- PD-1- treated mice (n=7 and n=4, respectively). They were subsequently 
treated for 5 hours with PMA/ionomycin (P/Io) plus brefeldin for the last 2 hours, and cytokine production was assessed by flow 
cytometry. (B) Representative plots of data showed in (A). Percentages of IFNγ+, IL-4+, IL-17+ and IL-21+ subpopulations are 
included. (C) Histograms show CD69 expression in Tfh from different conditions stimulated as in (A) to confirm effective cell 
activation. (D) Quantification of IFNγ, IL-4, IL-17 and IL-21 expression in P/Io- stimulated and control naïve CD4+ T lymphocytes 
from peripheral blood and spleen of anti- PD-1- treated and isotype- treated mice. Naïve T lymphocytes were isolated and pooled 
from seven isotype- treated mice and four anti- PD-1- treated mice, respectively. (E) Histograms show CD69 expression in T- naïve 
cells from different conditions stimulated as in (A) to confirm effective cell activation. *P<0.05; ****p<0.0001.
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number (figure 5C). These results indicate that anti- PD-1 
treatment increases the number of tumor TLS in parallel 
with a reduction in tumor burden, through a mechanism 
that may involve CCL21.
To analyze Tfh- mediated B cell activation in TLS, we 
examined PD-1 and Ki67 expression in these structures 
(figure 6A). We found a significant increase of positive 
cells for either marker in TLS from anti- PD-1- treated 
tumors, specifically in GC- like areas (figure 6B). Remark-
ably, anti- PD-1 responsive mice showed higher propor-
tion of Ki67+ cells and a significant increment in PD-1+ 
cells in tumor TLS than non- responsive mice (figure 6C). 
Moreover, the increased proportion of PD-1+ and Ki67+ 
cells in TLS positively correlated with expansion of cTfh 
in peripheral blood from anti- PD-1- treated mice, whereas 
the percentage of spleen Tfh did not show any significant 
correlation with these markers (figure 6D). In the light of 
these findings, we sought to evaluate the potential contri-
bution of TLS to the observed antibody response, so we 
examined mRNA expression level of soluble IgG1, IgG2b, 
IgG3 and IgM in tumor samples from anti- PD-1- treated 
and isotype- treated mice. We detected a strong expres-
sion of IgG1 together with lower levels of IgG2b, IgG3 
and soluble IgM, which slightly increased in PD-1- treated 
mice (figure 7A). To identify the specific site of IgG 
production in these tissues, we performed IgGk) staining 
of tumor sections, and we could determine that TLS were 
indeed a prominent source of IgG (figure 7B). Moreover, 
we found a significant increase of IgGk- positive TLS in 
anti- PD-1- treated as compared with isotype- treated mice 
(figure 7B). Likewise, augmented proportion of IgGk- 
producing TLS correlated with both expansion of cTfh in 
anti- PD-1- treated mice and increased presence of PD-1+ 
GCs in tumor TLS (figure 7C).
Altogether, these data suggest that anti- PD-1 treatment 
induces B cell activation and increased antibody produc-
tion within tumor TLS, associated with cTfh increase in 
peripheral blood.
DISCUSSION
Immunotherapy with checkpoint inhibitors has shown 
to be effective in a relevant percentage of patients with 
lung cancer, leading to increased survival rates.16–18 Here, 
we describe a novel mechanism of action of anti- PD-1 
antibodies using a mouse squamous lung cancer model, 
which unveils a previously unknown role for PD-1 in the 
immune response against these tumors. Hence, anti- PD-1 
promotes a significant increment in activated cTfh with 
increased B activation capacity. In parallel, this treatment 
Figure 3 Antiprogrammed cell death protein 1 (anti- PD-1) therapy promotes an antibody- mediated immune response. (A) 
Quantification of serum IgM levels from healthy mice (n=3), and anti- PD-1- treated (n=14) and isotype- treated (n=13) tumor- 
bearing mice. (B) Flow cytometry staining of B16 (red) and KLN205 (blue) tumor cells with IgG from serum derived from healthy 
and tumor- bearing mice. Percentages of positive B16 and KLN205 cells are indicated. *P<0.05; **p<0.01.
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induces CCL21 production in tumors, together with an 
increment in TLS number related to impaired tumor 
growth. Of note, cTfh percentage correlates with the 
presence of PD-1- expressing and Ki67- positive prolifer-
ating cells specifically in TLS, which is associated with 
the production of antibodies able to recognize tumor 
cells and may collaborate in antitumor response (online 
supplemental figure 5).
We used KLN205 murine lung squamous carcinoma 
cell line as a model for in vivo experiments.22 However, 
human NSCLC are more frequently adenocarcinomas 
(40%)23; therefore, despite anti- PD-1- mediated increase 
in cTfh probably relies on tumor type- independent mech-
anisms (see below in discussion), it will be of interest to 
confirm that our results are not restricted to squamous 
carcinoma by performing further experiments with addi-
tional NSCLC histological subtypes.
Immunohistochemistry experiments show an incre-
ment of PD-1- expressing cells in spleen GCs from mice 
treated with anti- PD-1 antibody (figure 4B) that correlates 
with that of Ki67 proliferation marker (figure 4C,D). 
Nevertheless, we did not detect a parallel Tfh increase in 
anti- PD-1- treated spleens by flow cytometry (figure 1B), 
which may be explained by Tfh redistribution towards 
GCs on treatment. In this regard, PD-1 plays a dual 
role in Tfh positioning in the follicle: PD-1 inhibits Tfh 
recruitment into GCs through its interaction with PD- L1 
expressed by bystander B cells; and PD-1 promotes GC 
confinement of Tfh expressing high PD-1 levels through 
CXCR3 downregulation.15 Anti- PD-1 might also promote 
differentiation of naïve CD4+ cells into Tfh, leading to 
an overall increase in Tfh number and contributing to 
the observed cTfh increment. Accordingly, previous 
reports have shown an expansion of Tfh population in 
Figure 4 Antiprogrammed cell death protein 1 (anti- PD-1) treatment induces germinal centers (GC) reaction in spleen. (A) 
Immunohistochemical images of spleen sections from isotype- treated or anti- PD-1- treated mice. Sections were stained for 
PD-1 and Ki67. Arrowheads indicate positive staining in GCs for PD-1 (left panels) and Ki67 (right panels). Scale bars represent 
500 µm. (B) Left, percentage of PD-1+ GCs in spleen sections of anti- PD-1- treated and isotype- treated mice; right, average 
percentage of PD-1+ cells in GCs present in spleen sections from anti- PD-1- treated and isotype- treated mice (n=20 and n=18, 
respectively). (C) Left, percentage of Ki67 GCs in spleen sections of anti- PD-1- treated and isotype- treated mice; right, average 
percentage of Ki67+ cells in GCs present in spleen sections from anti- PD-1- treated and isotype- treated mice (n=20 and n=18, 
respectively). (D) Correlation between either percentage of Ki67 and PD-1+ GCs (left) or average Ki67 and PD-1 cells inside GCs 
(right) (n=38). Pearson’s r is shown for each correlation. (E) Correlation between tumor size and either percentage of PD-1+ GCs 
(left) or percentage of Ki67+ GCs (right) (n=21). Pearson’s r is shown for each correlation. ***P<0.001; ****p<0.0001.
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PD-1 knockout mice15 24 25; also, overexpression of PD-1 
in CD4+ T cells reduces Tfh presence in SLOs after 
immunization.15 Some authors have described mouse 
Tfh- like populations that egress from SLOs prior to GC 
reaction in a SAP- independent manner.4 These cTfh 
include a CCR7loPD-1hiCXCR5+CD4+ subset with partial 
effector phenotype, which clearly resembles that of the 
cTfh population induced by anti- PD-1 in our experi-
ments (figure 1D,E). CCR7loPD-1hi cTfh correlate with 
active Tfh differentiation, and are characterized by both 
a strong helper activity and the ability to further migrate 
into SLOs where they support GC reaction.4 In humans, 
influenza vaccination transiently induces a CD38+ICOS+ 
cTfh population that includes antigen- specific cells. 
These antigen- specific cells are highly activated and 
synthesize increased amounts of IL-21.26 Anti- PD-1 treat-
ment induces a CD38+ cTfh population (figure 1D) with 
increased IL-21 production (figure 2A), which is consis-
tent with an activated phenotype. Likewise, effector 
capacity of human cTfh associates with the expression 
of specific surface molecules.27 Thus, CXCR3− cells, 
which include both Tfh2 (CCR6−) and Tfh17 (CCR6+) 
subsets, correspond to cTfh with increased effector prop-
erties. CCR7loPD-1hi phenotype associates with high ICOS 
expression and defines a population with the highest 
helper potential within each subtype. Our findings show 
that anti- PD-1- induced CCR7loPD-1hicTfh population 
has a reduced CXCR3 expression compared with cTfh 
in control mice (figure 1D), which is probably related to 
enhanced B cell activation capacity. Accordingly, these 
cells produce high levels of Tfh2 cytokines on stimu-
lation with P/Io (figure 2A). Of note, this population 
correlates with the presence of both PD-1- expressing 
and Ki67+ proliferating cells in TLS (figure 6D), which 
strongly suggests a role for cTfh on B cell activation in 
these structures. In the same line of thinking, combining 
treatment with anti- CTLA-4 and anti- PD-1 promotes Tfh 
infiltration in tumors with a parallel increment in IL-21 
production, through a potential direct effect of these 
antibodies on Tfh cells. Moreover, tumor response to this 
therapy in animal models is highly dependent on CD4+ 
cells and Ig production by B cells.28 Similarly, recent 
reports indicate that the presence of B cell- rich TLS is 
a strong indicator of response to anti- PD-1 treatment in 
patients with melanoma, renal cell carcinoma and soft- 
tissue sarcomas.29–31 Furthermore, anti- CTLA-4 therapy 
in humans and in a murine melanoma model induces 
a CD4+ PD-1hi population both in peripheral blood and 
Figure 5 Tertiary lymphoid structures (TLS), number increases with antiprogrammed cell death protein 1 (anti- PD-1) therapy. 
(A) Left panel, quantification of TLS number per tumor from isotype- treated or anti- PD-1- treated mice (n=50 and n=34, 
respectively); right panel, correlation between TLS number and tumor size (n=46). R- squared is shown as a goodness- of- fit 
measure. (B) Quantification of expression of CCL21 chemokine, measured by quatitative real- time PCR (qRT- PCR) in whole 
tumor sections from isotype- treated and anti- PD-1- treated mice (n=7 and n=6, respectively). (C) Left panel, quantification of 
expression of CCL21 by qRT- PCR in anti- PD-1- treated tumor sections with or without presence of TLS (n=11). Right panel, 
correlation between level of expression of CCL21 and TLS number in anti- PD-1- treated tumors (n=9). Spearman's coefficient r 
is shown. CCL21 expression in anti- PD-1- treated tumors was normalized to average CCL21 expression level in isotype- treated 
tumors. *P<0.05; ****p<0.0001.
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tumors. These cells impair CD8+ effector function in a 
PD-1/PD- L1- dependent fashion and favor tumor evasion 
mechanisms.32 Further administration of anti- PD-1 leads 
to a decrease in CD4+ PD-1hi population and restores 
CD8+ antitumor activity. However, anti- CTLA4- induced 
CD4+ PD-1hi cells show comparable B helper activity to 
that of their CD4+ PD-1− counterparts. Accordingly, anti-
tumor activity of anti- CTLA-4 does not seem to rely on B 
cell activation, since tumors developed in SAP knockout 
mice are responsive to anti- CTLA-4 therapy.32
Recent reports posit a role for PD-1 as tumor suppressor 
in lung cancer immunodeficient models, and provide 
evidence that anti- PD-1 antibodies may promote both in 
vitro tumor cell proliferation and in vivo tumor growth in 
PD-1- expressing lung cancers.33 34 However, these models 
are void of immune compartment, and the overall impact 
of combined tumor and immune PD-1 blockade has not 
been evaluated. In this regard, anti- PD-1- mediated tumor 
regression in PD-1- positive tumors could be directly related 
to immune tumor infiltration and anti- PD-1- mediated T 
cell activation potential. Hence, effective T cell activation 
would counteract enhanced tumor progression poten-
tially associated with this treatment. We propose that anti- 
PD-1- mediated increase in cTfh population and humoral 
response could collaborate in antineoplastic response 
secondary to immune system activation in this setting. 
Nevertheless, a comprehensive analysis of both tumor 
PD-1 and immune infiltration degree in patient samples 
is required to accurately establish their influence in anti- 
PD-1 therapy outcome.35 In this regard, tumor PD- L1 
expression in NSCLC biopsies is considered as a predic-
tive parameter of response, and its evaluation is routinely 
performed to establish the indication of PD-1/PD- L1 
inhibitors. However, clinical trials aimed at evaluating the 
predictive value of PD- L1 show contradictory results.36 37 
In addition, assessing PD- L1 expression in tumor biopsies 
involves an invasive procedure with additional risk. On 
the contrary, the implementation of cTfh immunopheno-
typing by flow cytometry in peripheral blood would be an 
affordable minimal invasive test that could provide valu-
able information about potential response to anti- PD-1 
treatment in these patients.
Figure 6 Antiprogrammed cell death protein 1 (anti- PD-1) treatment promotes tertiary lymphoid structures (TLS) activation. (A) 
Immunohistochemical images of tumor sections from anti- PD-1- treated and isotype- treated mice stained for PD-1 (left panels) 
(n=21 and n=16, respectively) and Ki67 (right panels) (n=19 and n=20, respectively). Arrowheads indicate positive staining for 
PD-1 and Ki67, respectively. Scale bars represent 250 µm and 500 µm in left and right images, respectively. (B) Percentage of 
PD-1+ and Ki67+ cells in TLS from tumors of isotype- treated and anti- PD-1- treated mice. (C) Correlation between tumor size 
and percentage of either PD-1+ (left) (n=24) or Ki67+ (right) (n=21) cells in TLS. R- squared as a goodness- of- fit measure or 
Pearson’s r are shown. (D) From left to right, correlation between percentage of circulating T follicular helper cells (cTfh) and 
either PD-1+ (n=22) or Ki67+ (n=24) cells in TLS, and between percentage of spleen follicular helper T cells (Tfh) and either PD-
1+ (n=20) or Ki67+ (n=23) cells in TLS. Spearman’s coefficient (first and third panels) or Pearson’s r (second and fourth panels) 
are shown for each correlation. ***P<0.001.
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In addition to Tfh expansion, PD-1 deficiency leads to 
an increase in Tfr cells with enhanced suppressor ability 
especially in peripheral blood, which suggests a role for 
PD-1 in Tfr generation together with PD-1- dependent 
limitation of Tfr release from SLOs.38 In contrast, we 
found a significant decrease in the proportion of circu-
lating Tfr on anti- PD-1 treatment (figure 1F). This 
finding indicates that anti- PD-1 primarily affects cTfh in 
our model, and further supports a role for this molecule 
at different stages of Tfh development.
Parallel to tumor progression, we observe a systemic 
humoral response evidenced both by the increment in 
serum IgM (figure 3) and by the presence of active GCs in 
SLOs, further enhanced by anti- PD-1 treatment (figure 4 
and online supplemental figure 2B). This humoral 
response includes circulating antitumor antibodies that 
can be detected in both isotype- treated and anti- PD-1- 
treated mice (figure 3). Accordingly, the increase in active 
GC number promoted by anti- PD-1 does not correlate with 
response to therapy (figure 4E). On the other hand, anti- 
PD-1 treatment upregulates TLS number, which is indeed 
associated with a positive response to therapy (figure 5A). 
Moreover, cTfh increase secondary to anti- PD-1 treatment 
correlates with augmented local Ig production supported 
by TLS (figure 7B,C). Thus, despite TLS might generate 
antibodies that go out into peripheral blood and be 
detected in serum,39 we hypothesize that cTfh- associated 
local Ig production in TLS is a main effector of antitumor 
humoral response induced by anti- PD-1.
Humoral response triggered by tumor growth also 
involves the appearance of autoantibodies (online supple-
mental figure 1), which strongly suggests the presence 
of a paraneoplastic process. Paraneoplastic syndromes 
appear in up to 10% of patients with lung cancer.40 In 
squamous carcinoma they are predominantly related to 
hypercalcemia and to the development of autoimmune 
conditions.40 41 Many of these syndromes preferentially 
involve cytotoxic T cell activation that secondarily leads 
to the generation of non- pathogenic autoantibodies, 
which are not always detectable.42 In most patients, para-
neoplastic manifestations either improve or disappear on 
tumor treatment.41 On the other hand, anti- PD-1 leads to 
autoimmune- related side effects in a reduced number of 
cases.43 In our model, anti- PD-1 therapy slightly reduces 
autoantibody titer, thus reflecting a possible improvement 
of autoimmune condition, accompanied or not by the 
development of immune- related toxicity with predomi-
nant T cell involvement.
The presence of TLS associates with a favorable prog-
nostic in several malignancies, including lung cancer.44 
In our NSCLC model, TLS increase induced by anti- 
PD-1 inversely correlates with tumor size (figure 5B), 
which is in accordance with data previously obtained in 
patients.44 TLS generation in solid tumors is regulated by 
Figure 7 Antiprogrammed cell death protein 1 (anti- PD-1) therapy promotes in situ antibody generation in tertiary lymphoid 
structures (TLS). (A) Relative expression of secreted IgG1, IgG2b, IgG3 and IgM isotypes in whole tumor sections of anti- PD-1- 
treated and isotype- treated mice (n=13). Ig expression was normalized between tumor samples using membrane- bound IgM. 
(B) Left, percentage of TLS positive for IgG kappa (IgGk) staining in tumor sections from anti- PD-1- treated and isotype- treated 
mice (n=18). Right, immunohistochemical image of tumor section stained for IgGk. Dashed lines indicate TLS boundaries. Scale 
bars represent 500 µm. (C) Correlation between percentage of IgGk- positive TLS and either percentage of circulating T follicular 
helper cells (cTfh) (left panel) (n=26) or PD-1+ germinal centers (GC) in TLS (right panel) (n=23) in anti- PD-1- treated mice. R- 
squared is shown as a goodness- of- fit measure. **P<0.01.
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mediators similar to those required for GC formation in 
SLOs. Thus, a specific 12- gene signature was described 
able to predict TLS presence within the tumor,45 which 
comprises an array of chemokines involved in different 
steps of TLS formation. Among these chemokines, 
CCL21 mediates homing of DC and CCR7+ naïve T 
cells, which contribute to generate ectopic lymphoid 
structures in both CCL21 transgenic mice and chron-
ically inflamed tissues.46 47 The major role played by 
CCL21 in antitumor immune responses is suggested 
by the increase in tumor infiltrating CD8+ lymphocytes 
and the induction of systemic antitumor response on 
intratumor injection of CCL21 gene- modified DC in 
patients with lung cancer.48 Remarkably, our data show 
a specific increase in tumor CCL21 expression when 
treated with anti- PD-1 (figure 5B). This chemokine 
could participate in cTfh recruitment to anti- PD-1- 
induced TLS, where these Tfh with increased B activa-
tion capacity would promote local antibody generation 
and collaborate in tumor response to therapy. Both 
stromal fibroblasts and cells present in high endothelial 
venules (HEV) have been proposed as main sources of 
CCL21 in TLS.49 We neither analyzed the cell type(s) 
responsible for nor the mechanism involved in CCL21 
production in response to anti- PD-1, so further research 
is required to understand these issues. In addition to 
CCL21 increase, we detected a significant reduction in 
the expression of other chemokines involved in TLS 
formation. However, some of them have been also asso-
ciated with tumor progression. For instance, CXCL13 is 
induced by carcinogenic agents,50 and is implicated in 
the development of some neoplasms as lung cancer.51 
Likewise, CXCL13 expression in tumors is related with 
poor survival outcome in different malignancies,52 53 
thus the observed CXCL13 decrease induced by anti- 
PD-1 (online supplemental figure 3B) could contribute 
to control tumor progression. However, CXCL13 expres-
sion is linked to a favorable outcome in melanoma, soft 
tissue sarcoma and colorectal cancer.30 31 54 Hence, it 
would be of great interest to evaluate the precise role of 
CXCL13 in tumor development in our model, and the 
actual effect of anti- PD-1 therapy on CXCL13 expression 
in human NSCLC. Similarly, CXCL12 is known to exert 
protumorigenic and prometastatic actions in NSCLC,55 
which could be partially counteracted by the decreased 
production of this chemokine on anti- PD-1 treatment 
(online supplemental figure 3B). Finally, CD103+ DC- de-
rived CXCL9 has been proposed to mediate response to 
anti- PD-1 therapy in a murine model of colon cancer by 
facilitating DC- T cell interactions.56 In this article, the 
authors detected an early increase in CXCL9 expres-
sion only 24 hours after starting anti- PD-1 treatment; 
however, we did not find changes in this chemokine at 
later stages (online supplemental figure 3B). These data 
suggest that CXCL9 could participate at initial phases of 
response to anti- PD-1 treatment, not related with cTfh 
increase.
CONCLUSIONS
We provide evidence for an anti- PD-1- induced cTfh popu-
lation with increased B activation capacity, which partici-
pates in tumor response to anti- PD-1 therapy in NSCLC. 
Likewise, we show an increase in the TLS number in 
anti- PD-1- treated tumors, which correlates with reduced 
tumor growth. These structures support cTfh- associated 
local antibody production, which is enhanced by anti- 
PD-1 treatment and may participate in host immune 
response against NSCLC tumors. These findings suggest 
a novel role of PD-1 in antineoplastic immune response, 
and support the existence of new mechanisms of action 
for anti- PD-1 therapy.
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